COTI-2, distinguished as a low-toxicity anticancer agent, is an orally bioavailable third-generation p53 activator that can reactivate mutant forms of p53 and concurrently inhibit the PI3K/AKT/mTOR signaling pathway. It has been shown to trigger apoptosis across various human tumor cell lines and possesses antitumor properties in head and neck squamous cell carcinoma (HNSCC) through both p53-dependent and independent mechanisms, effectively restoring mutant p53 to a wild-type structure[1].[2].[3].
COTI-2 动物研究
Animal study
Furthermore, COTI-2 prominently suppresses tumor growth in HT-29 human colorectal tumor xenografts at a dosage of 10 mg/kg, effectively reducing tumor sizes at specific intervals post-treatment and extending the period for tumors to reach certain sizes. Remarkably, COTI-2 also significantly curtails tumor growth in the SHP-77 small cell lung cancer (SCLC) xenograft model with doses as minimal as 3 mg/kg. In treatments involving U87-MG tumors, COTI-2 not only shrinks tumor volumes at designated times after treatment but also prolongs the duration needed for the growth of U87-MG xenografts in nude mice[2].
Ovarian Cancer
... 展开 >> Fallopian Tube Cancer
Endometrial Cancer
Cervical Cancer
Peritoneal Cancer
Head and Neck Cancer
HNSCC 收起 <<
Phase 1
Recruiting
December 2018
United States, Illinois
... 展开 >>
Northwestern Memorial Hospital
Recruiting
Chicago, Illinois, United States
Contact: Wilberto Nieves-Neira, MD 312-472-4684
Principal Investigator: Wilberto Nieves-Neira, MD
United States, Texas
MD Anderson Cancer Centre
Recruiting
Houston, Texas, United States
Contact: Shannon Westin, MD 713-794-4314
Principal Investigator: Shannon Westin, MD 收起 <<
Ovarian Cancer
... 展开 >> Fallopian Tube Cancer
Endometrial Cancer
Cervical Cancer
Peritoneal Cancer
Head and Neck Cancer
HNSCC 收起 <<
Phase 1
Recruiting
December 2018
United States, Illinois
... 展开 >>
Northwestern Memorial Hospital
Recruiting
Chicago, Illinois, United States
Contact: Wilberto Nieves-Neira, MD 312-472-4684
Principal Investigator: Wilberto Nieves-Neira, MD
United States, Texas
MD Anderson Cancer Centre
Recruiting
Houston, Texas, United States
Contact: Shannon Westin, MD 713-794-4314
Principal Investigator: Shannon Westin, MD 收起 <<
搜索
